Cargando…

Spinal Cord Involvement in MS and Other Demyelinating Diseases

Diagnostic accuracy is poor in demyelinating myelopathies, and therefore a challenge for neurologists in daily practice, mainly because of the multiple underlying pathophysiologic mechanisms involved in each subtype. A systematic diagnostic approach combining data from the clinical setting and prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrodan, Mariano, Gaitán, María I., Correale, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277673/
https://www.ncbi.nlm.nih.gov/pubmed/32455910
http://dx.doi.org/10.3390/biomedicines8050130
_version_ 1783543173023268864
author Marrodan, Mariano
Gaitán, María I.
Correale, Jorge
author_facet Marrodan, Mariano
Gaitán, María I.
Correale, Jorge
author_sort Marrodan, Mariano
collection PubMed
description Diagnostic accuracy is poor in demyelinating myelopathies, and therefore a challenge for neurologists in daily practice, mainly because of the multiple underlying pathophysiologic mechanisms involved in each subtype. A systematic diagnostic approach combining data from the clinical setting and presentation with magnetic resonance imaging (MRI) lesion patterns, cerebrospinal fluid (CSF) findings, and autoantibody markers can help to better distinguish between subtypes. In this review, we describe spinal cord involvement, and summarize clinical findings, MRI and diagnostic characteristics, as well as treatment options and prognostic implications in different demyelinating disorders including: multiple sclerosis (MS), neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody-associated disease, and glial fibrillary acidic protein IgG-associated disease. Thorough understanding of individual case etiology is crucial, not only to provide valuable prognostic information on whether the disorder is likely to relapse, but also to make therapeutic decision-making easier and reduce treatment failures which may lead to new relapses and long-term disability. Identifying patients with monophasic disease who may only require acute management, symptomatic treatment, and subsequent rehabilitation, rather than immunosuppression, is also important.
format Online
Article
Text
id pubmed-7277673
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72776732020-06-12 Spinal Cord Involvement in MS and Other Demyelinating Diseases Marrodan, Mariano Gaitán, María I. Correale, Jorge Biomedicines Review Diagnostic accuracy is poor in demyelinating myelopathies, and therefore a challenge for neurologists in daily practice, mainly because of the multiple underlying pathophysiologic mechanisms involved in each subtype. A systematic diagnostic approach combining data from the clinical setting and presentation with magnetic resonance imaging (MRI) lesion patterns, cerebrospinal fluid (CSF) findings, and autoantibody markers can help to better distinguish between subtypes. In this review, we describe spinal cord involvement, and summarize clinical findings, MRI and diagnostic characteristics, as well as treatment options and prognostic implications in different demyelinating disorders including: multiple sclerosis (MS), neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody-associated disease, and glial fibrillary acidic protein IgG-associated disease. Thorough understanding of individual case etiology is crucial, not only to provide valuable prognostic information on whether the disorder is likely to relapse, but also to make therapeutic decision-making easier and reduce treatment failures which may lead to new relapses and long-term disability. Identifying patients with monophasic disease who may only require acute management, symptomatic treatment, and subsequent rehabilitation, rather than immunosuppression, is also important. MDPI 2020-05-22 /pmc/articles/PMC7277673/ /pubmed/32455910 http://dx.doi.org/10.3390/biomedicines8050130 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Marrodan, Mariano
Gaitán, María I.
Correale, Jorge
Spinal Cord Involvement in MS and Other Demyelinating Diseases
title Spinal Cord Involvement in MS and Other Demyelinating Diseases
title_full Spinal Cord Involvement in MS and Other Demyelinating Diseases
title_fullStr Spinal Cord Involvement in MS and Other Demyelinating Diseases
title_full_unstemmed Spinal Cord Involvement in MS and Other Demyelinating Diseases
title_short Spinal Cord Involvement in MS and Other Demyelinating Diseases
title_sort spinal cord involvement in ms and other demyelinating diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277673/
https://www.ncbi.nlm.nih.gov/pubmed/32455910
http://dx.doi.org/10.3390/biomedicines8050130
work_keys_str_mv AT marrodanmariano spinalcordinvolvementinmsandotherdemyelinatingdiseases
AT gaitanmariai spinalcordinvolvementinmsandotherdemyelinatingdiseases
AT correalejorge spinalcordinvolvementinmsandotherdemyelinatingdiseases